-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HodHg0iMFvy9wQhaGj5g8LGyVbGWL3zcG8NTx1uvcmLWa1CtZ9sd5sKUhSpd0OnA rtow8AUZ2kwuaytMBOPixg== 0000950133-97-000526.txt : 19970223 0000950133-97-000526.hdr.sgml : 19970223 ACCESSION NUMBER: 0000950133-97-000526 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19970221 SROS: NONE GROUP MEMBERS: BB BIOTECH AG GROUP MEMBERS: BIOTECH TARGET, S.A. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: TRANSKARYOTIC THERAPIES INC CENTRAL INDEX KEY: 0000885259 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 043027191 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-47221 FILM NUMBER: 97540663 BUSINESS ADDRESS: STREET 1: 195 ALBANY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02138 BUSINESS PHONE: 6173490200 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] STATE OF INCORPORATION: DC FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: C/O BAKER & MCKENZIE STREET 2: 815 CONNECTICUT AVENUE NW CITY: WASHINGTON STATE: DC ZIP: 20006 BUSINESS PHONE: 2028351882 MAIL ADDRESS: STREET 1: C/O BAKER & MCKENZIE STREET 2: 815 CONNECTICUT AVENUE NW CITY: WASHINGTON STATE: DC ZIP: 20006 SC 13G 1 SCHEDULE 13G RE: TRANSKARYOTIC THERAPIES, INC. 1 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2 Under the Securities Exchange Act of 1934 TRANSKARYOTIC THERAPIES, INC. ----------------------------- (Name of Issuer) COMMON STOCK, PAR VALUE $.01 PER SHARE -------------------------------------- (Title of Class of Securities) 893735-10-0 ----------- (CUSIP Number) Check the following box if a fee is being paid with the statement [ ]. (A fee is not required only if the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.) Page 1 of 10 Pages 2 CUSIP No. 893735-10-0 13G - --------------------- - ---------------------------------------------------------------------- (1) Name of Reporting Persons S.S. or I.R.S. Identification No. of Above Persons BB Biotech AG - ---------------------------------------------------------------------- (2) Check the Appropriate Box if a Member (a) [ ] of a Group* (b) [x] - ---------------------------------------------------------------------- (3) SEC Use Only - ---------------------------------------------------------------------- (4) Citizenship or Place of Organization Swiss - ---------------------------------------------------------------------- Number of Shares (5) Sole Voting Power Beneficially Owned 0 by Each Reporting ------------------- Person With (6) Shared Voting Power 1,300,000 ---------------------- (7) Sole Dispositive Power 0 ------------------- (8) Shared Dispositive Power 1,300,000 ------------------- - ---------------------------------------------------------------------- (9) Aggregate Amount Beneficially Owned by Each Reporting Person 1,300,000 - ---------------------------------------------------------------------- (10) Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* [ ] - ---------------------------------------------------------------------- (11) Percent of Class Represented by Amount in Row (9) 7.83 - ---------------------------------------------------------------------- (12) Type of Reporting Person* HC, CO - ---------------------------------------------------------------------- Page 2 of 10 Pages 3 CUSIP No. 893735-10-0 13G - --------------------- - ---------------------------------------------------------------------- (1) Name of Reporting Persons S.S. or I.R.S. Identification No. of Above Persons Biotech Target, S.A. - ---------------------------------------------------------------------- (2) Check the Appropriate Box if a Member (a) [ ] of a Group* (b) [x] - ---------------------------------------------------------------------- (3) SEC Use Only - ---------------------------------------------------------------------- (4) Citizenship or Place of Organization Panama - ---------------------------------------------------------------------- Number of Shares (5) Sole Voting Power Beneficially Owned 0 by Each Reporting ------------------- Person With (6) Shared Voting Power 1,300,000 --------------------- (7) Sole Dispositive Power 0 ------------------- (8) Shared Dispositive Power 1,300,000 ------------------- - ---------------------------------------------------------------------- (9) Aggregate Amount Beneficially Owned by Each Reporting Person 1,300,000 - ---------------------------------------------------------------------- (10) Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* [ ] - ---------------------------------------------------------------------- (11) Percent of Class Represented by Amount in Row (9) 7.83 - ---------------------------------------------------------------------- (12) Type of Reporting Person* CO - ---------------------------------------------------------------------- Page 3 of 10 Pages 4 Securities and Exchange Commission Washington, D.C. Schedule 13G ITEM 1(a). NAME OF ISSUER: Transkaryotic Therapies, Inc. ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: 195 Albany Street, Cambridge, MA 02139 ITEM 2(a). NAME OF PERSON FILING: Biotech Target, S.A. ("Biotech Target") BB Biotech AG ("BB Biotech") ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: Biotech Target's business address is Swiss Bank Tower, Panama 1, Republic of Panama. BB Biotech AG's business address is Vordergasse 3, 8200 Schaffhausen, CH/Switzerland. ITEM 2(c). CITIZENSHIP: BB Biotech: Swiss Biotech Target: Panamanian ITEM 2(d). TITLE OF CLASS OF SECURITIES: Common Stock, (par value $.01 per share) Page 4 of 10 Pages 5 ITEM 2(e). CUSIP NUMBER: 893735-10-0 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b), OR 13d-2(b), CHECK WHETHER THE PERSON FILING IS A: Not Applicable ITEM 4. OWNERSHIP. (a) Amount beneficially owned: 1,300,000 (b) Percent of class: 7.83% (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 1,300,000 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: 1,300,000 ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS. Not Applicable ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON. Not Applicable ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY. Not Applicable ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP. See Exhibit I which is incorporated herein by reference. Page 5 of 10 Pages 6 ITEM 9. NOTICE OF DISSOLUTION OF GROUP. Not Applicable. ITEM 10. CERTIFICATION. Not Applicable. Statement is being filed pursuant to Rule 13d-1(c). SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. BB BIOTECH AG Date: February 21, 1997 By:/s/ Hans-Joerg Graf* -------------------- Name: Hans-Joerg Graf By:/s/ Dr. Victor Bischoff* ------------------------ Name: Dr. Victor Bischoff BIOTECH TARGET, S.A. Date: February 21, 1997 By:/s/ Dr. Andreas Bremer ---------------------- Name: Dr. Andreas Bremer By:/s/ Daniel Bugman ----------------- Name: Daniel Bugman - ---------------- * See power of attorney, attached as an exhibit 99.E to BB Biotech's Schedule 13D relating to Biogen, Inc. filed with the Securities and Exchange Commission on June 2, 1994. Page 6 of 10 Pages 7 EXHIBIT INDEX Exhibit I Identification and Classification of Members of the Group Exhibit II Statement of BB Biotech AG Exhibit III Statement of Biotech Target, S.A. Page 7 of 10 Pages 8 EXHIBIT I This statement is being filed jointly by BB Biotech AG, a Swiss corporation ("BB Biotech") and Biotech Target S.A., a Panamanian corporation ("Biotech Target"). Biotech Target is a wholly owned subsidiary of BB Biotech. Page 8 of 10 Pages 9 EXHIBIT II BB Biotech AG ("BB Biotech") disclaims beneficial ownership of the securities referred to in the Schedule 13G to which this exhibit is attached, and the filing of this Schedule 13G shall not be construed as an admission that BB Biotech is, for the purpose of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, the beneficial owner of any securities covered by this Schedule 13G. Pursuant to Rule 13d-1(f)(1) and subject to the preceding disclaimer, BB Biotech affirms that it is individually eligible to use Schedule 13G and agrees that this Schedule 13G is filed on its behalf. BB BIOTECH AG Date: February 21, 1997 By:/s/ Hans-Joerg Graf ------------------- Name: Hans-Joerg Graf By:/s/ Dr. Victor Bischoff ----------------------- Name: Dr. Victor Bischoff Page 9 of 10 Pages 10 EXHIBIT III Pursuant to Rule 13d-1(f)(1), Biotech Target, S.A. affirms that it is individually eligible to use Schedule 13G and agrees that this Schedule 13G is filed on its behalf. BIOTECH TARGET, S.A. Date: February 21, 1997 By:/s/ Dr. Andreas Bremer ---------------------- Name: Dr. Andreas Bremer By:/s/ Daniel Bugman ----------------- Name: Daniel Bugman Page 10 of 10 Pages -----END PRIVACY-ENHANCED MESSAGE-----